Bentley Pharmaceuticals, Inc. has secured capacity at Cardinal Health’s North Raleigh, NC facility for the scale-up and manufacture of clinical supplies of its intranasal insulin product candidate, facilitating the expansion of clinical trials.

The product candidate utilizes Bentley’s CPE-215 drug delivery technology to deliver insulin directly through diabetic patients’ nasal mucosa using a small, discreet nasal spray. Cardinal Health will manufacture clinical supplies of Bentley’s insulin product under cGMP at its new, sterile manufacturing facility in North Raleigh.

“This agreement with Cardinal Health is another important step forward in our intranasal insulin program and the CPE-215 delivery platform,” said John A. Sedor, president of Bentley Pharmaceuticals. “Early results for the intranasal insulin product have been promising and there is growing interest in alternative insulin delivery methods that are less intrusive than injection. We are excited to be working with Cardinal Health to continue to advance this program through global Phase II trials this year.”

“Bentley Pharmaceuticals leveraged multiple capabilities within Cardinal Health’s development and manufacturing segment to prepare its intranasal insulin candidate for global clinical trials,” said Shawn Gallagher, vice president and general manager of Cardinal Health’s North Raleigh facility. “By using Cardinal Health’s full range of solutions Bentley Pharmaceuticals maximizes its efficiency and relies on the same high-quality services through the entire drug development and commercialization cycle.”